We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.48 | 0.75% | 332.63 | 332.52 | 332.77 | 335.91 | 328.00 | 330.65 | 390,457 | 16:23:50 |
From Jul 2023 to Jul 2024
By Ben Glickman
Xeris Biopharma has entered an exclusive worldwide license agreement with Amgen related to a subcutaneous formulation of a Thyroid Eye Disease treatment.
The Chicago-based biopharmaceutical company said Amgen would develop, manufacture and commercialize the formulation of teprotumumab using Xeris' XeriJect technology.
Xeris may receive up to $75 million based on development and regulatory milestones in addition to sales milestones. The company will also get royalties on future sales of Tepezza, which is the brand name of teprotumumab in the U.S., using XeriJect technology.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 10, 2024 08:38 ET (13:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
